Sign up
Pharma Capital

Genprex retains pharma branding agency to select a name for its lead drug

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive Investors the biotech has moved one step closer to commercializing its flagship drug candidate Oncoprex by retaining pharmaceutical branding agency Addison Whitney.

Varner says Addison Whitney is helping with the naming process of the drug, which could take a few months to a year.

 

View full GNPX profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.